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ABSTRACT
Paraneoplastic pemphigus (PNP) is a life-threatening autoimmune mucocutaneous blis-
tering disease associated with malignancy, particularly lymphoproliferative neoplasms. 
Clinically, it is characterized by severe and intractable mucositis and polymorphous 
cutaneous eruptions, ranging from blisters to lichenoid lesions. The histologic features 
are also diverse according to the morphology of the clinical lesions, ranging from 
suprabasal acantholysis to interface changes with necrotic keratinocytes. PNP is char-
acterized by the production of autoantibodies against the plakin family proteins as well 
as the desmoglein 1 and 3, which are target antigens of ordinary pemphigus. Thus, 
indirect immunofluorescence on substrates other than skin is useful in the diagnosis of 
PNP. The presence of anti-desmoglein antibodies have been demonstrated by enzyme-
linked immunosorbent assay. The gold standard for the diagnosis of PNP however, is 
the detection of the characteristic circulating autoantibodies against 210-kDa envo-
plakin and 190-kDa periplakin by immunoblotting or immunoprecipitation. It is now 
accepted that both humoral and cellular immunities are involved in the pathogenesis of 
PNP. Anti-desmoglein 3 antibodies are known to play a pathogenic role in the initiation 
of acantholytic blister formation. Autoreactive CD8 + cytotoxic T cells induced by anti-
tumor immune response are also involved in the development of mucocutaneous man-
ifestations and bronchiolotis obliterans. The prognosis of PNP depends on the nature 
of the underlying neoplasm, with high mortality rate due to sepsis or multi-organ fail-
ure, particularly bronchiolitis obliterans. Although the combined use of immunosup-
pressive agents and rituximab has been administered in treating PNP, to date, there are 
no consistently effective treatments for PNP.
Copyright © 2010, Taiwanese Dermatological Association. 
Published by Elsevier Taiwan LLC. All rights reserved.
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Introduction
Paraneoplastic pemphigus (PNP) was first described in 1990 
by Anhalt et al1 as a mucocutaneous autoimmune syndrome 
associated with neoplasms, most commonly of lymphopro-
liferative origin. The original criteria for diagnosis of PNP 
included: (1) painful mucosal erosions and a polymorphous 
skin eruption; (2) histopathologic features of intraepidermal 
acantholysis, dyskeratosis, and vacuolar interface dermati-
tis; (3) direct immunofluorescence findings of immunoglob-
ulin(Ig)G and complement deposition at the keratinocyte 
cell surfaces and/or along the basement membrane zone; 
(4) serum autoantibodies detected by indirect immunofluo-
rescence that bind to cell surfaces of stratified squamous 
epithelia as well as simple, columnar, and transitional epi-
thelium; and (5) serum immunoprecipitation with a complex 
of four proteins of 250, 230, 210 and 190 kDa.
The concept of PNP has evolved and many clinical vari-
ations have been described since then. Recently, the more 
inclusive term of paraneoplastic autoimmune multi-organ 
syndrome, was introduced to encompass those patients who 
show the heterogeneous clinical features and autoantibody 
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for the diagnosis of PNP, there have been a few case reports 
of PNP without any obvious underlying neoplasm.37–39
Clinical features
The clinical manifestations of PNP are highly variable, 
however, painful and intractable mucositis is a constant 
feature of PNP.36,40,41 The stomatitis usually presents as ex-
tensive erosions and ulcerations affecting all surfaces of the 
oropharynx with preferential involvement of the lateral 
borders of the tongue.1,3,36 The ulcers typically extend onto 
the vermilion of the lips, resulting in the characteristic 
hemorrhagic crusts (Figure 1). The mucosal involvement of 
PNP is more extensive, necrotic and extremely resistant to 
therapy than that of pemphigus vulgaris, and in some cases, 
lichenoid lesions are also found.42 The mucositis of PNP 
can extend to the pharynx, larynx and esophagus, causing 
soreness and dysphagia.36 The involvement of conjunctival 
mucosa is frequent with occasional progression to visual 
impairment.40–45 The anogenital and gastrointestinal mu-
cosa can also be affected.2,46 Mucositis appears to be the 
initial presentation in nearly half of PNP patients.47 More-
over, there have been several reports of PNP patients who 
presented with localized mucosal involvement as the sole 
manifestation.25,48,49
Cutaneous lesions are polymorphic, ranging from blisters 
to lichenoid lesions, and can vary in the same patient ac-
cording to the stage of the disease (Figures 1 and 2).47 The 
vesicles, flaccid blisters and erosions that mimic pemphi-
gus vulgaris usually affect the upper trunk, head and neck, 
and proximal extremities; they might also coalesce to con-
fluent erosions resembling toxic epidermal necrolysis. Tense 
blisters resembling bullous pemphigoid are also described 
in PNP with a predilection for distal extremities.20,42,50 The 
other characteristic cutaneous lesions in PNP are lichenoid 
eruptions consisting of infiltrated and erythematous macules, 
papules and plaques resembling lichen planus and graft-
versus-host disease.20 In addition, targetoid lesions resem-
bling erythema multiforme are also observed. In the chronic 
form of the disease, the lichenoid lesions may develop at 
the sites of previous blisters and become the predominant 
features. However, there have been increasing reports of 
PNP cases in which the lichenoid eruptions are the only 
cutaneous manifestations.8,51–53 Cummins et al51 reported 
four PNP patients with clinical features of lichenoid erup-
tions in the absence of detectable antibodies and described 
these cases as lichenoid variants of PNP. Lichenoid lesions 
are more commonly observed in childhood and adolescent 
PNP patients.54 Skin lesions may be psoriasiform, vegeta-
tive, or pustular eruptions, and sometimes involve the palm 
and sole.41 Alopecia has also been found in PNP patients 
with corresponding immunofluorescence findings in the 
intercellular spaces of the follicular epithelium.53,55
profiles of PNP.2 The term suggests that internal organs other 
than the skin and mucous membranes are also targeted by 
this autoimmune reaction. Indeed, the deposits of autoanti-
bodies in different organs, such as lung, muscle, bladder and 
kidney have been demonstrated in autopsy specimens, and 
respiratory involvement with clinical features of bronchioli-
tis obliterans are also observed in many cases of PNP.2
Neoplasms associated with paraneoplastic 
pemphigus
Almost all cases of PNP are associated with tumors, mostly 
with hematologic malignancies.1,3 One review studied 
163 cases of PNP and reported that hematologic-related 
neoplasms or disorders were associated with 84% of the 
cases, with non-Hodgkin lymphoma (NHL) (38.6%) as the 
most frequent, followed by chronic lymphocytic leukemia 
(CLL) (18.4%) and Castleman’s disease (18.4%).3 Other re-
ported hematologic conditions associated with PNP in-
cluded thymoma, Waldenström macroglobulinemia, Hodgkin 
lymphoma and anaplastic large cell lymphoma.3 The non-
hematologic neoplasms associated with PNP were com-
prised of epithelial-origin carcinomas or mesenchymal-origin 
sarcomas. Of the 39 cases of PNP associated with non-
hematologic neoplasm reported in the English literature be-
tween 1990 and 2008, a total of 19 cases were related to 
carcinoma, and 20 cases were related to sarcoma.
The carcinomas associated with PNP include adenocar-
cinoma of the colon,4,5 pancreas,6,7 breast,8 prostate,9,10 
liver,11,12 and squamous cell carcinoma of the tongue,13 
uterus14 and kidney.15 In one case, bronchogenic carcinoma 
was described.16 An association with cutaneous malignan-
cies such as basal cell carcinoma,17 malignant melanoma,18 
and two kinds of cutaneous T cell lymphoma3,19 have also 
been reported. Of the 20 cases of sarcoma, seven were fol-
licular dendritic cell sarcomas (35%)20–26 and four were 
inflammatory myofibroblastic tumors (20%).27–30 There was 
one case each of liposarcoma,31 leiomyosarcoma,32 malig-
nant nerve sheath tumor,33 poorly differentiated sarcoma1 
and reticulum cell sarcoma.34 In three cases, details of the 
type of sarcoma were not provided.3 PNP associated with 
sarcoma, especially with follicular dendritic cell sarcoma 
and inflammatory myofibroblastic tumor, seems to be more 
common than previously reported. In children, the most 
common neoplasm associated with PNP is Castleman’s dis-
ease.35 In about two-thirds of the cases, the underlying 
malignancy preceded the clinical manifestations of PNP.36 
Finally, Lee et al25 reported a case of PNP that developed 
shortly after removal of the associated tumor.
However, in one-third of patients, there was no known un-
derlying malignancy at the time of initial mucocutaneous 
eruption. Therefore, PNP can be a marker for occult malig-
nancy. Although it has been suggested that a tumor is essential 
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Figure 1 Characteristic clinical features of paraneoplastic pemphigus (PNP). Severe 
involvement of oral and conjunctival mucosa is typical for PNP. (A,B) Severe erosions, 
ulcerations, and hemorrhagic crusts on the vermilion borders of lips. (C,D) Polymorphous 
cutaneous eruptions, with erythematous macules, papules, flaccid bullae, and erosions 
on the trunk and extremities.
Histological features
The histological features of PNP vary according to the lesion 
sampled because of the varied morphologies of the clinical 
lesions. Samples from noninflammatory bullae or erosions 
show suprabasal acantholysis with sparse inflammatory in-
filtrates. Whereas, in lichenoid lesions, the biopsy specimen 
may show vacuolar interface change with necrotic keratino-
cytes and satellite lymphocytic infiltration resembling ery-
thema multiforme or lichenoid infiltrates, as well as interface 
dermatitis with dyskeratotic keratinocytes resembling lichen 
planus. Lesions with a mixed clinical pattern might show 
mixed histological features of concomitant acantholysis 
and lichenoid interface dermatitis. The underlying immuno-
logic mechanism may shed light to the spectrum of clinical 
and histological features for a given case of PNP.2,47 If the 
dominant mechanism of mucocutaneous lesions of PNP is 
antibody-mediated cytotoxicity, bullae and erosions resem-
bling classic pemphigus with suprabasal and/or intraepider-
mal blisters might be prominent. In contrast, if the dominant 
mechanism is cell-mediated cytotoxicity, lichenoid skin 
lesions with lymphocytic interface dermatitis and dyskera-
totic keratinocytes might be prominent (Figure 3).
Immunopathology
PNP is characterized by the production of autoantibodies 
against various target antigens, mainly plakin family proteins 
and desmogleins (Table 1).56 The most characteristic and 
consistently recognized plakin antigens are envoplakin57 
and periplakin58 (210 and 190 kDa, respectively), followed 
by desmoplakins I and II (250 and 210 kDa, respectively). 
Bullous pemphigoid antigen 1 (BPAG1, 230 kDa), plectin 
(> 500 kDa), plakoglobin, and the unidentified 170 kDa 
antigen are the less frequently recognized antigens from 
PNP patient sera. The presence of anti-desmoglein (Dsg) 3 
and anti-Dsg 1 autoantibodies in PNP sera also have been 
demonstrated by enzyme-linked immunosorbent assay 
(ELISA).59
Envoplakin, periplakin, desmoplakin, BPAG1 and plec-
tin all belong to the plakin family proteins.60 Envoplakin 
and periplakin have been shown to bind to each other and 
co-localize with desmoplakin at desmosomal plaques and 
on keratin filaments in keratinocytes, suggesting that they 
serve as a scaffold for cornified cell envelope assembly.61 
Plakin proteins are present in simple and transitional 
epithelium as well as in stratified epithelium; in contrast, 
desmogleins are only expressed in stratified epithelial 
tissues.60,61 There fore, indirect immunofluorescence (IIF) of 
plakin proteins yields a positive reaction not only on nor-
mal human skin, but also on monkey esophagus, rat blad-
der, myocardium, and rat lung.62 This might explain why 
PNP is the only form of pemphigus in which internal organs 
can be affected by autoimmune injury. Diagnosis of PNP 
depends on the demonstration of serum autoantibodies 
against plakin proteins which can be detected with IIF, im-
munoblotting, and immunoprecipitation.
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pattern of DIF was IgG and/or C3 deposition on the ICS 
alone.40 The combined ICS and basement membrane zone 
deposition of IgG and/or C3 was observed in less than 50% of 
PNP patients.40 In addition, false-negative DIF is more com-
monly noticed in PNP than in other forms of pemphigus.63,64
Indirect immunofluorescence (IIF)
Since PNP is characterized by the presence of autoantibod-
ies against plakin family proteins that are present in simple, 
transitional, columnar as well as stratified squamous epi-
thelia, IIF on substrates other than skin is useful in the diag-
nosis of PNP. An IIF study of PNP sera showed cell surface 
binding of IgG on both normal human skin and other 
Diagnostic methods
Direct immunofluorescence
Direct immunofluorescence (DIF) is a useful technique in 
the diagnosis of PNP; it works by detecting IgG autoanti-
bodies bound to the keratinocyte cell surfaces of perile-
sional skin and mucosa (Figure 4). Three main patterns of 
DIF have been noted in PNP patients: (1) deposition of IgG 
and/or its complement in the epidermal intercellular spaces 
(ICS); (2) granular/linear deposition of IgG and/or its com-
plement along the basement membrane zone; and (3) a 
combination of the above two patterns.41 A previous histo-
logic review showed that the most frequently observed 
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Figure 2 The diversity of clinical manifestations of paraneoplastic pemphigus. (A) Erythematous 
to violaceous papules and plaques resembling lichen planus. (B) Targetoid lesions resembling 
erythema multiforme. (C) Irregular patches of alopecia resembling alopecia areata. (D,E) 
Subungal hyperkeratosis and onychodystrophy resembling lichen planus.
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In addition, IIF on rat bladder is known to be highly specific 
(83%) in the diagnosis of PNP because rat bladder is rich in 
desmoplakins and lacks desmogleins.40,66,67 As a result, IIF 
using rat bladder is now considered to be a useful screen-
ing test for PNP. However, it should be noted that about 
25% of PNP serum samples shows negative reactivity with 
IIF using rat bladder.41 Therefore, more sensitive and spe-
cific tests such as immunoblotting and immunoprecipita-
tion are often needed to confirm the diagnosis of PNP.
Immunoblotting, immunoprecipitation and ELISA
Immunoblotting and immunoprecipitation have been con-
sidered as the gold standard for the diagnosis of PNP. Im-
munoprecipitation can detect antibodies against multiple 
epidermal antigens including plakin family proteins and 
an unidentified 170-kDa protein.40,68 Immunoblot analysis 
of normal human epidermal extracts has shown that PNP 
sera constantly react with the 210-kDa envoplakin and 
190-kDa periplakin (Figure 6).40,68 This characteristic reac-
tivity with two plakin proteins is highly sensitive and specific 
for PNP. The detection of plectin by either immunoblotting 
substrates including rat bladder, monkey esophagus, myocar-
dium and rat lung (Figure 5).62 The prevalence of positive 
IIF staining however, varies with the substrate used because 
each substrate has a different antigen profile and proper-
ties.41,65 It has been reported that IIF on normal human skin 
is positive in up to 50% of cases, whereas IIF on rat bladder 
epithelium has been found to be more sensitive (75%).66,67 
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Figure 3 Histological features of paraneoplastic pemphigus (PNP). (A) Suprabasal acantholysis mimicking pemphigus vulgaris. (B) In the same 
lesion, acantholysis and interface dermatitis with scattered dyskeratotic cells. (C) Erythema multiforme or (D) lichen planus-like interface dermati-
tis are characteristic features of PNP (H&E, 200×).
Table 1 Autoantigens of paraneoplastic pemphigus (PNP) and 
detection methods.
Autoantigen MW (kD) Detection method
Plectin 500 IP + IB
Desmoplakin I 250 IP or IB
BP230 230 IP or IB
Desmoplakin II 215 IP or IB
Envoplakin 210 IP or IB
Periplakin 190 IP or IB
Unknown 170 IP
Dsg1 160 ELISA
Dsg3 130 ELISA
MW = molecular weight; IP = immunoprecipitation; IB = immunoblotting; 
ELISA = enzyme-linked immunosorbant assay; Dsg = desmoglein.
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pemphigus. According to a previous study70 with 129 pem-
phigus patients (81 with pemphigus vulgaris and 48 with 
pemphigus foliaceus), the sensitivity and specificity of Dsg 3 
ELISA were 97.5% and 97.8%, respectively, while the sen-
sitivity and specificity of Dsg 1 ELISA were 97.9% and 
98.9%, respectively. Anti-Dsg 3 and anti-Dsg 1 autoantibod-
ies have been shown to be pathogenic in PNP. The majority 
or immunoprecipitation is difficult because of its large 
size (518 kDa). For that reason, the sequential immunopre-
cipitation and immunoblot analysis has been used as a 
more sensitive technique for the detection of anti-plectin 
autoantibodies.69
ELISA for recombinant Dsg 1 and Dsg 3 is a highly sen-
sitive and specific diagnostic tool for the diagnosis of 
A B
Figure 4 Direct immunofluorescence in paraneoplastic pemphigus. (A) Deposition of immunoglobulin G on the keratinocyte cell surfaces and 
(B) complement (C3) along the basement membrane zone.
D
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Figure 5 Indirect immunofluorescence in paraneoplastic pemphigus. Circulating immunoglobulin G antibodies bind to multiple epithelia in-
cluding (A) esophagus, (B) rat bladder, (C) lung, and (D) rat myocardium.
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in their report on PNP patients with prominent lichenoid 
mucositis or dermatitis. Their revised diagnostic criteria in-
cluded the presence of antiplakin and/or anti-desmoglein 
autoantibodies, lack of correlation of mucocutaneous dis-
ease with anti-Dsg 3 and Dsg 1, respiratory injury evolving 
to bronchiolitis obliterans, and lichenoid mucocutaneous 
lesions.
Currently, the four features that have been consistently 
found in the majority of PNP patients are generally ac-
cepted as the minimal criteria of PNP with a high degree of 
confidence. These include (1) clinical features of severe 
and protracted mucosal involvement and polymorphic cu-
taneous eruptions, (2) histologic features of acantholysis or 
lichen oid or interface dermatitis, (3) demonstration of an-
tiplakin autoantibodies, and (4) the presence of an underly-
ing neoplasm, especially lymphoproliferative tumors.76
DIF is now thought to be non-essential for the diagnosis 
of PNP because of the frequent false negatives.63,64 IIF on 
rat bladder epithelia and monkey esophagus is accepted as 
an adequate screening test for PNP. However, IIF is not 
highly reliable, and immunochemical techniques are con-
sidered more precise. Therefore, a negative IIF does not 
exclude the diagnosis of PNP, and further tests with im-
munochemical techniques such as immunoblotting and 
immunoprecipitation should be performed to confirm or 
veto a diagnosis.
Pathogenesis
The mechanisms by which the underlying neoplasms in-
duce autoimmunity have been proposed in many previous 
studies (Figure 7).8,20,50,77,78
Foreign tumor antigens cross-react with 
epidermal antigens
One explanation is that PNP results from an antitumor 
immune response cross-reacting with the normal epithelial 
proteins and thereby inducing autoimmunity by molecular 
mimicry.77,78 This theory is based on the hypothesis that the 
tumors constitutively or anomalously express epithelial 
proteins.63 In line with this theory, thymomas and Castle-
man’s disease have been noted to express desmoplakin.36 
To date, however, there is no evidence that the majority of 
PNP-associated tumors such as NHL and CLL produce 
desmosomal proteins including desmoplakins.
Epitope spreading
Epitope spreading refers to the development of immune 
responses to epitopes, which are distinct from and non-
cross-reactive with the disease-causing epitopes; this may 
lead to propagation of autoimmunity.79,80 This process has 
of patients with PNP have been reported to have circulating 
anti-Dsg3 IgG as determined by ELISA, although patients 
without anti-Dsg autoantibodies have also been reported.71 
A recent study72 using an epitope mapping technique, dem-
onstrated that the linker subdomains of envoplakin and 
periplakin contain major antigenic epitopes targeted by 
autoantibodies in PNP patients. ELISAs using recombinant 
proteins containing linker subdomains of envoplakin and 
periplakin expressed in a human cell line as the antigens were 
reported to be highly sensitive and specific for the diagno-
sis of PNP.73 In addition, a specific bead-based assay using 
the recombinant envoplakin-linker subdomain-conjugated 
beads was also shown to be a useful diagnostic technique 
with high sensitivity (69.7%) and specificity (94.6%) in 33 
PNP patients.74
Diagnostic criteria
Recently, there has been a surge in the number of reports of 
PNP patients who did not satisfy all of the diagnostic criteria 
originally proposed by Anhalt et al.1 As a result, the di-
agnostic criteria for PNP have been revised. Camisa and 
Helm75 have proposed major and minor criteria. The major 
criteria include polymorphic mucocutaneous eruption, con-
current internal neoplasia and characteristic serum immu-
noprecipitation findings. The minor criteria include histologic 
evidence of acantholysis, DIF showing intercellular and 
basement membrane staining, and positive cytoplasmic 
staining of rat bladder by IIF. Patients must satisfy three major, 
or two major and two minor criteria to be diagnosed with 
PNP. Later on, Mimouni et al54 developed their own criteria 
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Figure 6 Immunoblotting analysis against human epidermal extracts. 
Control pemphigus vulgaris (PV) serum reacts with the 160-kD anti-
Dsg 1 and 130-kD Dsg 3 (lane 1); control bullous pemphigoid (BP) 
serum reacts with BP 230 and BP 180 (lane 4); paraneoplastic pemphi-
gus (PNP) serum reacts with the 210-kD envoplakin and the 190-kD 
periplakin (lanes 2 and 3).
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develop a humoral immune response characteristic of 
PNP. In one of their patients, the initial immunoprecipita-
tion study identified only two antigens, 170- and 250-kDa 
antigen with IIF on rat bladder result negative. However, 
the patient’s condition deteriorated after one year, and re-
peated immunoprecipitation detected five major PNP 
antigens (250-kDa, 210-kDa, 230-kDa, 190-kDa and 170-
kDa antigens), and IIF on rat bladder also showed positive 
reactivity. This case clearly illustrate epitope spreading: 
the disease progressed from a primary autoimmune reac-
tion that developed some PNP antigens, which then in-
duced a subsequent autoimmune reaction to all major PNP 
antigens.
Dysregulated cytokine production by tumor cells
This hypothesis proposes that dysregulated cytokine pro-
duction by tumor cells may induce the development of 
autoimmunity. IL-6 is known to promote differentiation 
been proposed as a possible mechanism for autoimmune 
skin diseases.79 Many case reports have noted that an in-
flammatory disease was followed by the development 
of an antibody-mediated bullous disease. For example, bul-
lous pemphigoid following lichen planus81 or psoriasis82 
and mucous membrane pemphigoid following Steven-
Johnson syndrome.83 Chan et al79 suggested that an au-
toimmune or inflammatory process directed against the 
basement membrane would results in tissue damage such 
that hidden antigens become exposed and evoke a second-
ary or primary autoimmune response, respectively. Bowen 
et al8 described five cases of patients who were diagnosed 
as having PNP with concomitant features of lichen planus. 
They suggested that epitope spreading might have a role in 
the pathogenesis of PNP, and proposed that lichenoid der-
matosis, which might preexist or be induced by the under-
lying neoplasm, disrupted the dermoepidermal junction 
and exposed des mosomal or hemidesmosomal antigens to 
autoreactive lymphocytes. The patients would subsequently 
Immune response to tumor
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Figure 7 Pathogenesis of paraneoplastic pemphigus (PNP). Both humoral and cellular immunity are involved in the pathogenesis of PNP. 
Autoimmune cellular cytotoxic reactions may be generated by an antitumor immune response. These autoreactive CD8 + cytotoxic T cells can in-
duce pulmonary injury resulting in bronchiolitis obliterans. Lichenoid interface dermatitis can also be induced by these cytotoxic T cells, thereby 
generating humoral immune response through the mechanism of epitope spreading. The tumor itself can produce autoantibodies against antigens 
in epidermis or produce the large amount of IL-6, resulting in the activation of B cells and autoantibody production. Autoantibodies against Dsg 3 
can induce acantholysis, thus initiating the blister formation. Autoantibodies against plakin family proteins are constantly present in the sera of 
PNP patients. However, its role in pathogenicity remains unknown.
Paraneoplastic pemphigus 9
Humoral and cellular immunity in the 
pathogenesis of paraneoplastic pemphigus
Humoral immunity
Using ELISA, Amagai et al59 found anti-Dsg 3 antibodies in 
all 25 PNP patients, and anti-Dsg 1 antibodies in 16 of these 
patients. The authors demonstrated that anti-Dsg 3-specific 
antibodies from PNP sera can cause blisters by injection in 
neonatal mice. Reversely, removal of anti-Dsg 3 antibodies 
was sufficient to eliminate the ability of PNP sera to induce 
blisters. Recently, the same authors identified anti-Dsg 3 IgG 
in canine PNP serum and showed that these autoantibodies 
could cause dissociation of keratinocytes in canine PNP.91 
Based on these observations, they suggested that Dsg 3 and 
Dsg 1 are the cell surface target antigens in PNP and that 
anti-Dsg 3 antibodies play a pathogenic role in the initia-
tion of blister formation. They proposed that anti-Dsg 3 au-
toantibodies initiate the primary acantholytic process, damage 
the cell membranes, and subsequently induce the produc-
tion of autoantibodies to the intracellular proteins of plakin 
family, thereby resulting in the disease condition. The con-
stant mucosal involvement and typical histological features 
of suprabasal acantholysis in PV and PNP might be explained 
by the presence of anti-Dsg 3 autoantibodies.
However, Nguyen et al92 demonstrated that autoantibod-
ies against nondesmosomal targets, possibly including ke-
ratinocyte cholinergic receptor, of patients with pem phigus 
are also pathogenic and that IgG from PNP patients can 
induce extensive skin blistering with suprabasilar acanthol-
ysis in Dsg 3-knockout mice. Based on these findings, they 
proposed that anti-Dsg 3 antibody may not be necessary for 
the development of mucocutaneous lesions in patients with 
PNP. In addition, several patients with PNP were reported 
to have no detectable circulating anti-Dsg 3 autoantibodies 
using ELISA.53,93 A recent study using recombinant Dsg 3 
with its extracellular domain expressed in mammalian cells, 
as the ELISA antigen also reported that only 11 of 16 PNP 
sera showed positive reactivity.73 In spite of the absence of 
anti-Dsg 3 IgG, these patients showed clinical manifestations 
of PNP including mucosal involvement and acantholytic 
lesions, except in one case,53 where the patient had no mu-
cosal involvement or reactivity with Dsg 3 and Dsg 1 using 
ELISA. These cases support the possibility that acantholysis 
in PNP may be induced by antibodies against epithelial 
antigens other than Dsg 3 or cell-mediated immunity.
Although the pathogenicity of anti-Dsg autoantibodies 
in PNP has been demonstrated previously, the pathogenic 
role of anti-plakin autoantibodies in PNP remains unknown. 
Since most of the sera from PNP patients recognize several 
members of plakin family, including desmoplakin I and II, 
BPAG1, envoplakin, periplakin and plectin by immunopre-
cipitation and immunoblotting, autoantibodies against plakin 
proteins are considered to be the most constant diagnostic 
and maturation of B cells as well as the production of 
immunoglobulins and acute phase reactants; in addition, it 
also stimulates the activity of cytotoxic T cells and NK cells.84 
Markedly elevated serum IL-6 levels have been demon-
strated in a majority of PNP patients.85 Furthermore, it has 
been observed that in a subset of tumors associated with 
PNP, such as NHL, CLL and Castleman’s disease, the tumor 
cells secrete large amounts of IL-6 in vitro.86 These tumors 
are characterized by dysregulated IL-6 production and are 
known to be associated with other autoimmune phenome-
non. For example, CLL has been reported to be associated 
with autoimmune thrombocytopenia, pure red cell aplasia 
and Coomb’s positive hemolytic anemia.87 Castleman’s dis-
ease is known to be associated with myasthenia gravis; in 
those with Castleman’s disease-associated autoimmune phe-
nomenon, the administration of anti-IL-6 antibodies as a 
treatment has been effective.88 This evidence suggests that 
dysregulated cytokine production, including up-regulation 
of IL-6 by tumor cells is responsible for inducing the 
autoantibodies and stimulating cytotoxic T cells in the 
pathogenesis of PNP.
Lymphoid tumor itself produces autoantibodies 
against epithelial antigens
Recently, increasing evidence has shown support for the 
hypothesis that lymphoid tumor itself can produce autoan-
tibodies against epithelial antigens.20,50 Wang et al50 dem-
onstrated that cultured tumor cells from patients with PNP 
associated with Castleman’s disease produced autoantibodies 
that recognized normal human epidermal proteins of 210-
kDa and 190-kDa. These findings suggest that secreted au-
toantibodies from Castleman’s disease, which react against 
epidermal proteins might have an important role in the patho-
genesis of PNP. Later, the same group also found autoanti-
bodies against plakin family (periplakin, envoplakin, and 
desmoplakin) and Dsg 3 in cultured medium of thymoma 
and follicular dendritic cell sarcoma from PNP patients.20
B lymphocytes in these tumors carried a similarly rear-
ranged variable region of the immunoglobulin gene and a 
high incidence of somatic mutations in the complementarity-
determining regions and framework regions, suggesting that 
B cell clones from these hematological tumors can produce 
autoantibodies.89,90 Although it is not known whether these 
B cells originate in the tumor itself or migrate from other 
immunologic origins, this evidence supports the theory that 
B cells in the associated tumors produce autoantibodies 
against desmosomal and hemidesmosomal proteins, result-
ing in the development of PNP. While this theory could ex-
plain the pathogenesis of PNP associated with lymphoid 
tumors such as Castleman’s disease, thymoma, and follicu-
lar dendritic cell sarcoma, there is no evidence of the pro-
duction of autoantibodies from non-hematological solid 
tumors associated with PNP.
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Treatment and prognosis
The prognosis of PNP depends largely on the nature of the 
underlying malignancy.36 Patients with PNP associated with 
malignant tumors have poor prognosis and high mortality 
rate (90%).58 The course of PNP does not parallel with the 
course of the underlying malignancy.36 Mortality frequently 
results from a complication of immunosuppressive regimens 
such as sepsis, gastrointestinal bleeding due to high dose of 
corticosteroids, or bronchiolitis obliterans.63 In patients with 
malignant tumor, reducing the tumor burden does not equal 
to controlling the autoimmunity, and no individual therapeu-
tic regimen has been demonstrated to be consistently effec-
tive. Systemic corticosteroids are the first-line treatment. 
However, only two reports of PNP showed good response 
with steroids alone.100,101 In treating PNP, a combination of 
prednisone with other immunosuppressive regimens, such as 
cyclosporine,102 cyclophosphamide,96,103,104 azathioprine63 
or mycophenolate mofetil105 as well as intravenous immu-
noglobulins104 or plasmapheresis106–108 has been used and 
shown effective in a subset of patients. Several reports have 
highlighted the effectiveness of high-dose cyclophospha-
mide in combination with steroids. Intravenous cyclophos-
phamide without stem cell rescue in a patient with PNP 
showed a good and safe response.96 Mucositis is generally 
resistant to most therapeutic strategies.
Apart from conventional T cell-directed therapies such 
as cyclosporine and prednisone, daclizumab, a humanized 
monoclonal antibody to the alpha subunit of the IL-2 re-
ceptor of T cells, has been promising as a therapeutic agent 
of PNP. A small number of PNP patients showed good re-
sponse to a combination regimen of prednisone, daclizu-
mab, and rituximab, suggesting that downregulating both 
humoral and cell-mediated autoimmunity is effective in the 
treatment of PNP.51 Alemtuzumab, a monoclonal antibody 
directed against CD52, the high affinity IL-2 receptor, also 
looks to be a promising treatment, with one case where 
an ongoing long-term remission of PNP was induced by 
alemtuzumab in a patient with an underlying B cell chronic 
lymphocytic leukaemia.109
In contrast to patients with malignant tumor-associated 
PNP, cases associated with benign tumors, such as local-
ized Castleman’s disease and benign thymomas show 
better prognosis with improvement or remission when the 
tumor is removed.77 A case series of PNP associated with 
Castleman’s disease showed that total resection of the tu-
mors resulted in the improvement of cutaneous lesions within 
6–11 weeks, recovery from mucositis within 5–10 months, 
and decreased titer of serum antibody in 6–8 weeks in 7 
of the 10 patients.42 A similar beneficial effect of tumor re-
moval has also been reported in cases of PNP associated 
with benign thymoma.110 Therefore, early detection and 
complete resection of tumors are essential for the treatment 
of PNP associated with these benign tumors.
markers of PNP.47 In particular, antibodies against envo-
plakin and periplakin are the most consistently recognized 
in the serum of PNP patients by immunoblotting.36
Among the anti-plakin antibodies, autoantibodies di-
rected against desmoplakins I and II have been reported to 
have pathogenic effects in a subset of patients with erythema 
multiforme, as demonstrated by passive transfer studies into 
newborn mice.94 Li et al95 reported that application of purified 
autoantibodies against the linker subdomains of envoplakin 
and periplakin from PNP sera to cultured human epidermal 
keratinocytes induced the internalization of these anti-
bodies into the keratinocytes, and the retraction of keratin 
filaments from cell-cell borders in cultured human kerati-
nocytes. They concluded that in addition to anti-Dsg 3 anti-
bodies, autoantibodies against envoplakin and periplakin 
might also play a pathogenic role in PNP. However, a pre-
vious review54 found no significant correlations between 
the anti-plakin antibody pattern and clinical and immun-
opathological features of PNP. Whether these anti-plakin 
antibodies are produced primarily in the course of PNP and 
play a pathogenic role or they are just surrogate markers for 
the PNP remains to be further investigated.
Cellular immunity
With the increasing number of cases of PNP with lichenoid 
variant, it has been suggested that cell-mediated immune 
mechanisms play a role in the development of PNP. One pre-
vious report51 described four patients with PNP who pre-
sented with predominantly lichenoid mucocutaneous lesions 
but had no demonstrable circulating autoantibodies. Reich 
et al96 characterized T cells that infiltrated into the lichenoid 
cutaneous lesions of their PNP patient and demonstrated a 
selective epidermal accumulation of activated CD8 + T cells, 
with an increased local productions of interferon-γ and 
tumor necrosis factor-α, and strong expressions of HLA-DR 
and ICAM-1 on keratinocytes. In addition, Nguyen et al2 
demonstrated that the mononuclear cell infiltrates at the 
dermoepidermal junction in PNP lesions consisted of both 
MHC-restricted CD8 + cytotoxic T lymphocytes and non-
MHC-restricted CD56 + , CD68 + Natural killer (NK) cells. 
Based on these findings, they proposed that both direct 
cytotoxic reactions and antibody-dependent cellular cyto-
toxicity may mediate target-cell damages in PNP. More over, 
IL-6, which is known to be increased in PNP sera, has been 
observed to enhance the activity of both cytotoxic T cells 
and NK cells in vitro.97,98 In addition, T cells have also been 
reported to be necessary for the development of intralumi-
nal fibrosis associated with bronchiolitis obliterans, organ-
izing pneumonia using a reovirus 1/L-induced murine 
model.99 These findings further provide evidence for the 
important role of cellular immunity and suggest that both 
humoral and cellular immunity are involved in the patho-
genesis of PNP.
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Pulmonary involvement
Respiratory tract involvement with clinical features of bron-
chiolitis obliterans is frequently found in PNP and may cause 
irreversible respiratory failure and death.63 In a previous 
study121 of 28 cases of PNP associated with Castleman’s dis-
ease, 26 patients were diagnosed to have bronchiolitis ob-
literans. Another recent study42 also reported bronchiolitis 
obliterans in seven of the ten PNP cases associated with 
Castleman’s disease. It seems that pulmonary involvement 
is more likely to occur in patients with PNP associated with 
Castleman’s disease. The presence of desmoplakins in respi-
ratory epithelium63 coupled with the histologic findings of 
acantholysis in bronchial epithelium and DIF findings of lin-
ear deposition of IgG and complement along the lamina 
propria122 suggest that autoantibody-mediated injury may be 
implicated in the development of bronchiolitis obliterans.
Hoffman et al123 found intense infiltrates of CD8 + T cells 
in the bronchiolar wall of PNP patients, and suggested the 
involvement of CD8+ T lymphocytes in the progression of 
bronchiolitis. This evidence supports the hypothesis that both 
humoral and cell-mediated autoimmunities are involved in 
the development of bronchiolitis obliterans similar to mu-
cocutaneous lesions. Like mucositis, bronchiolitis obliter-
ans is also resistant to various immunosuppressive agents. 
Lung transplant is the only therapeutic option for the pro-
gressive respiratory failure secondary to bronchiolitis.124 Of 
note is that 20% or more of patients develop fatal bronchi-
olitis obliterans-like respiratory involvement, even after the 
mucocutaneous lesions are improved.63
Conclusion
PNP is a rare paraneoplastic autoimmune multi-organ syn-
drome that develops as the result of both humoral and cel-
lular immunities. The prognosis of PNP is poor and often 
fatal due to sepsis or multi-organ failure, particularly respi-
ratory failure with bronchiolitis obliterans. PNP is charac-
terized by the presence of autoantibodies against all of the 
plakin family proteins, which makes them the most consist-
ent diagnostic markers. However, the pathogenic roles and 
the origins of these anti-plakin autoantibodies remains still 
unknown. Thus, further studies are warranted to investigate 
the possible role of anti-plakin antibodies in tissue injury, 
and shed light to their role in the pathogenesis of PNP. In 
addition, it is also important further investigate the mecha-
nisms of pulmonary injury because bronchiolitis obliterans 
is a common cause of fatal respiratory failure in PNP pa-
tients, even after improvement of the mucocutaneous lesions. 
Currently, there is no standard treatment for PNP. Further 
clinical studies on a large patient group with a long-term 
follow-up are needed in order to find more effective treat-
ment strategies and reduce the high mortality rate.
To avoid the release of circulating autoantibodies from 
the tumors during operation, it is important to block the tumor 
blood supply and avoid squeezing the tumor.77 The intrave-
nous administration of immunoglobulins before and during 
the operation was reported to significantly reduce mortality 
due to bronchiolitis obliterans.77 After the complete exci-
sion of these benign tumors, continued immunosuppressive 
therapy is required for up to 2 years until the remission of 
the autoimmunity.63
Rituximab is a monoclonal humanized antibody directed 
against the B cell-specific, cell-surface antigen CD20, which 
was originally developed for the treatment of B cell lym-
phomas.111 Treatment with rituximab has been used for many 
autoimmune blistering diseases including refractory pem-
phigus and PNP.112 The therapeutic mechanism of rituxi-
mab in PNP is related to the depletion of both normal and 
abnormal CD20-expressing B cells, resulting in the reduc-
tion of autoantibody-producing neoplastic B cells and the 
decrease of abnormal immune response.112 Since 2001, 
rituximab therapy has been reported in eight cases of PNP 
within the English literature, with variable results.113–120 Two 
of these cases, which were associated with CD20-positive 
follicular NHL showed significant improvement of the mu-
cocutaneous lesions and partial remission of NHL after a 
single course of four weekly infusions of 375 mg/m2 of ritux-
imab with or without corticosteroid.113,114 One case with 
gastric B cell lymphoma showed significant improvement 
in skin lesion, but mild improvement in oral lesion after 
combined treatment with rituximab, corticosteroids, and 
mycophenolate mofetil.115 However, three cases associated 
with CD20-positive follicular NHL116–118 and one case each 
associated with Waldenström macroglobulinemia119 and 
follicular dendritic cell sarcoma120 showed only partial 
responses or unsuccessful results.
The adverse effects of rituximab are generally brief and 
infusion-related; these include headache, fever, chills, rash 
and hypotension. Serious adverse events such as opportu-
nistic infections are rare. However, infections are often fatal, 
possibly due to the underlying malignancy and/or immuno-
suppressive regimens.121,122 Because of the small number of 
cases, the efficacy of rituximab as a treatment of PNP cannot 
be established. However, rituximab seems to be less effective 
in treating PNP than pemphigus vulgaris, where rituximab 
has shown rapid healing of mucocutaneous lesions and long-
term remission in approximately 60–100% of the treated 
patients.112 The unsuccessful treatment of PNP patients can 
possibly be attributed to the presence of CD20-negative 
plasma cells and/or B cells that produce autoantibodies and 
the involvement of autoreactive T cells in the pathogenesis 
of PNP.116 Further case-control studies are required to estab-
lish the optimal dosage and cycle of rituximab administration, 
the possible need for other immunosuppressive therapies, 
the risk of severe adverse effects and the benefit of repeated 
rituximab infusions as maintenance therapy.
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